Abstract:Congenital aniridia is a complex disease, characterized mainly by iris and foveal hypoplasia, but patients show great clinical variability with overlapping of different anterior and posterior segment anomalies. More than 90% of patients carry heterozygous variants in the PAX6 gene, a highly conserved transcriptional regulator that plays a key role in normal ocular development. Loss‐of‐function variants causing premature stop codons are the most frequent within the broad mutational spectrum of PAX6 , with more than 750 different mutations identified to date. 11p13 microdeletions altering PAX6 or its downstream regulatory region have been found in ~25% of patients. Iris abnormalities are also present in various aniridia‐mimicking conditions, such as FOXC1 and PITX2 ‐related anterior segment dysgenesis, among other minor genes. Therefore, this is now recognized that genetic and clinical diagnosis of patients with suspected aniridia is challenging. Genetic testing has proven to be crucial for differential diagnosis. Here, we update best practices to improve genetic testing and clinical management of aniridia using more cost‐effective next‐generation sequencing analysis. Recent advances in genomic sequencing contributed to increasing diagnostic yield in congenital aniridia and allied conditions, from 70 to 95% as we demonstrated in a cohort of Spanish patients, and also in a “naïve” cohort of Hungarian patients without previous genetic testing. NGS allowed us to identify pathogenic PAX6 variants in patients with an atypical or incomplete presentation of aniridia, such as isolated foveal or optic nerve hypoplasia. In addition, genomic approaches contributed to elucidating new molecular mechanisms underlying the etiopathogenesis of congenital aniridia involving non‐coding PAX6 variants and revealed an unexpected role of mosaic variants in the intrafamilial variable expressivity of aniridia. Emerging long‐read sequencing techniques may provide insight into hidden sources of variation at PAX6 locus in some patients with unexplained genetic causes of aniridia. Nanopore‐based long‐read whole genome sequencing unveiled cryptic balanced chromosomal structural variants that directly disrupt PAX6 or its regulatory elements. In conclusion, NGS‐based genetic testing is crucial to ensure a correct and timely clinical diagnosis, and provide better prognosis and management of patients with aniridia or aniridia‐like, besides the further benefits to families by allowing prenatal and preimplantation genetic testing. Genetic findings would also be critical in defining eligible patients for future clinical trials.

Clinical research of family congenital aniridia caused by PAX6 mutation

A recurrent PAX6 mutation is associated with aniridia and congenital progressive cataract in a Chinese family.

A PAX6 Gene Mutation Causes Aniridia in a Chinese Family

Mutation Analysis of PAX6 Gene in a Large Chinese Family with Aniridia.

A Novel PAX6 Gene Mutation in a Chinese Family with Aniridia.

Identification Of One Novel Mutant Pax6 Allele In Chinese Congenital Aniridia And Cataract Family

A rare missense PAX6 mutation causes atypical aniridia in a three-generation Chinese family

The Systemic Genotype-Phenotype Characterization of PAX6-Related Eye Disease in 164 Chinese Families

A novel deletion downstream of the PAX6 gene identified in a Chinese family with congenital aniridia.

Diversity of clinical phenotypes in a cohort of Han Chinese patients with PAX6 variants

Pathophysiological characteristics of abnormal glucose metabolism in aniridia patients with PAX6 mutation

Genetic analysis using next-generation sequencing and multiplex ligation probe amplification in Chinese aniridia patients

Genetic Analysis by NGS and MLPA in Chinese Aniridia Patients

Ocular and Craniofacial Phenotypes in a Large Brazilian Family with Congenital Aniridia

Metabolic and neuroactivity imbalances in plasma from aniridia patients with PAX6 haploinsufficiency

A Novel 11p13 Microdeletion Encompassing PAX6 in a Chinese Han Family with Aniridia, Ptosis and Mental Retardation

Novel and recurrent variants in PAX6 in four patients with ocular phenotypes from Southeast Asia

Genetic background of congenital aniridia

Novel variants in the PAX6 gene related to isolated aniridia

Clinical and molecular aspects of congenital aniridia - A review of current concepts

Heterozygous PAX6 mutations may lead to hyper‐proinsulinaemia and glucose intolerance: A case–control study in families with congenital aniridia